Drugs / BMS-986020
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02227173 | Sep → Nov 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02101125 | Mar → May 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02068053 | Mar → Apr 2014 | immunodeficiency disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02017730 | Jan 2014 → Jan 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02588625 | Feb 2016 → Oct 2019 | diffuse scleroderma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT01766817 | Jan 2013 → Feb 2016 | idiopathic pulmonary fibrosis | Bristol-Myers Squibb | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588625 ↗ |
| Known as | AP-3152 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297270 ↗ |
| Known as | Bristol-Myers Squibb (BMS)-986020 | “Bristol-Myers Squibb (BMS)-986020 in healthy male subjects” NCT02068053 ↗ |
| Action | Inhibit | “BMS-986020 potently inhibited LPA1-induced fibrogenesis.” PMID 35303880 ↗ Mar 20221“Lysophosphatidic acid receptor Edg-2 antagonist” CHEMBL4297270 ↗ |
| Modality | Small molecule | — CHEMBL4297270 ↗ |
| Route | Oral | “BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks” NCT01766817 ↗ |
| Target | LPAR1 | “Lysophosphatidic acid receptor Edg-2 antagonist” CHEMBL4297270 ↗ |